Free Trial

Delcath Systems (DCTH) Competitors

Delcath Systems logo
$14.26 +0.30 (+2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$14.49 +0.23 (+1.64%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DCTH vs. CDRE, TNDM, INMD, LQDA, KMTS, BLFS, MDXG, ESTA, FNA, and RXST

Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include Cadre (CDRE), Tandem Diabetes Care (TNDM), InMode (INMD), Liquidia (LQDA), Kestra Medical Technologies (KMTS), BioLife Solutions (BLFS), MiMedx Group (MDXG), Establishment Labs (ESTA), Paragon 28 (FNA), and RxSight (RXST). These companies are all part of the "medical equipment" industry.

Delcath Systems vs.

Delcath Systems (NASDAQ:DCTH) and Cadre (NYSE:CDRE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Delcath Systems has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500. Comparatively, Cadre has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.

Cadre has a net margin of 6.34% compared to Delcath Systems' net margin of -150.70%. Cadre's return on equity of 12.88% beat Delcath Systems' return on equity.

Company Net Margins Return on Equity Return on Assets
Delcath Systems-150.70% -338.16% -104.02%
Cadre 6.34%12.88%6.06%

Delcath Systems received 17 more outperform votes than Cadre when rated by MarketBeat users. However, 55.17% of users gave Cadre an outperform vote while only 27.50% of users gave Delcath Systems an outperform vote.

CompanyUnderperformOutperform
Delcath SystemsOutperform Votes
33
27.50%
Underperform Votes
87
72.50%
CadreOutperform Votes
16
55.17%
Underperform Votes
13
44.83%

Delcath Systems currently has a consensus price target of $22.75, indicating a potential upside of 61.18%. Cadre has a consensus price target of $37.00, indicating a potential upside of 17.37%. Given Delcath Systems' higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than Cadre.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Delcath Systems
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cadre
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cadre had 9 more articles in the media than Delcath Systems. MarketBeat recorded 10 mentions for Cadre and 1 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.61 beat Cadre's score of 0.66 indicating that Delcath Systems is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Delcath Systems
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Cadre
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Cadre has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Delcath Systems$37.21M12.67-$47.68M-$0.98-14.40
Cadre$567.56M2.26$38.64M$0.9035.03

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 44.0% of Cadre shares are held by institutional investors. 17.9% of Delcath Systems shares are held by company insiders. Comparatively, 37.0% of Cadre shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Cadre beats Delcath Systems on 11 of the 17 factors compared between the two stocks.

Remove Ads
Get Delcath Systems News Delivered to You Automatically

Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DCTH vs. The Competition

MetricDelcath SystemsSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$471.45M$4.47B$5.70B$8.31B
Dividend YieldN/A32.62%4.55%4.02%
P/E Ratio-10.4528.9324.6319.33
Price / Sales12.6750.37395.7694.77
Price / CashN/A51.0838.1634.64
Price / Book19.606.287.114.48
Net Income-$47.68M$67.64M$3.20B$247.07M
7 Day Performance5.02%10.19%1.79%3.29%
1 Month Performance-0.95%-0.78%6.15%-2.63%
1 Year Performance202.90%24.93%15.19%4.77%

Delcath Systems Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCTH
Delcath Systems
3.3849 of 5 stars
$14.26
+2.1%
$22.75
+59.5%
+198.3%$476.33M$37.21M-10.5660
CDRE
Cadre
2.9661 of 5 stars
$32.45
-3.8%
$37.00
+14.0%
-9.0%$1.32B$567.56M39.092,240Insider Trade
TNDM
Tandem Diabetes Care
4.5153 of 5 stars
$19.71
+2.8%
$45.38
+130.2%
-31.9%$1.31B$940.20M-10.212,400Positive News
INMD
InMode
1.3916 of 5 stars
$18.35
+0.2%
$22.25
+21.3%
-7.1%$1.28B$394.82M7.81480
LQDA
Liquidia
2.3662 of 5 stars
$14.79
+2.5%
$25.38
+71.6%
-6.4%$1.25B$15.61M-9.0750Earnings Report
Analyst Revision
KMTS
Kestra Medical Technologies
N/A$24.78
+16.5%
N/AN/A$1.23B$45.82M0.00300
BLFS
BioLife Solutions
1.2874 of 5 stars
$25.92
+3.7%
$29.86
+15.2%
+41.8%$1.22B$82.25M-24.45440
MDXG
MiMedx Group
3.3422 of 5 stars
$8.04
+1.5%
$12.00
+49.3%
+0.7%$1.18B$348.88M14.62870Positive News
ESTA
Establishment Labs
2.4208 of 5 stars
$39.27
+6.0%
$57.40
+46.2%
-13.6%$1.13B$166.03M-15.22960
FNA
Paragon 28
1.3826 of 5 stars
$13.02
-0.1%
$14.20
+9.1%
+38.3%$1.09B$256.18M-17.59343,000
RXST
RxSight
3.27 of 5 stars
$26.50
+2.6%
$51.63
+94.8%
-48.7%$1.07B$139.93M-31.93220
Remove Ads

Related Companies and Tools


This page (NASDAQ:DCTH) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners